RR-HNK treatment for obsessive-compulsive disorder.
Official title: A Double-blind, Placebo-controlled Study to Determine the Safety and Feasibility of Two Doses of Intravenous (2R, 6R)-Hydroxynorketamine (RR-HNK) in Adults With Obsessive-Compulsive Disorder
Run by Stanford University · NCT06575075 · Data updated 2026-11-12
This pilot will test whether two intravenous doses of RR-HNK can reduce symptoms in adults with obsessive-compulsive disorder who have not fully responded to standard treatments.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 45 (estimated) |
| Sponsor | Stanford University Academic / other |
| Locations | 1 site (Palo Alto, California) |
| Status | Recruiting |
| Started | January 23, 2026 |
| Main results expected | November 30, 2028 |
| Study ends | November 30, 2029 |
| Registry record updated | August 12, 2026 |
| Trial ID | NCT06575075 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–65 with a diagnosis of OCD who have failed at least one first-line treatment (such as SRIs or CBT) or who have declined those treatments, who can comply with study procedures and provide informed consent, are ideal candidates.
✕Probably not a fit
People who are pregnant or nursing, have an allergy to ketamine, have a medical or psychiatric condition that investigators deem unsafe, or have a history of deep brain stimulation will likely be ineligible and not receive benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Participants will receive one of two dosage levels of intravenous RR-HNK or a placebo with close monitoring for safety and side effects. The protocol combines Phase 1 safety measures with Phase 2 preliminary efficacy endpoints using standardized OCD symptom scales and clinical interviews. The study includes procedures to explore how RR-HNK affects brain function that may relate to symptom change. Visits take place at Stanford and require fasting before infusion and adherence to medication and visit procedures.
Why it matters
Potential benefit: If successful, RR-HNK could provide a new, potentially faster-acting treatment option for people with OCD who have not benefited from standard therapies.
How similar studies have gone: Related approaches using ketamine and its metabolites have shown rapid symptom relief in depression and some case reports in OCD, but RR-HNK itself is a novel compound with limited human data to date.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ages 18-65 * Meet the criteria for OCD diagnosis * Failed at least 1 prior trial of standard first-line OCD treatment (e.g. SRI/CBT) or or had refused these treatments for individual reasons * Agree to the following lifestyle modifications: comply with requirements for fasting prior to --the infusion session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication study procedures. * Able to provide informed consent Exclusion Criteria: * Allergy or hypersensitivity to ketamine * Any current or past medical/psychiatric condition that makes participation unsafe in the opinion of the investigator or study physician * Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control * Lifetime history of deep brain stimulation
Where it's running
-
Stanford University School of Medicine
Palo Alto, California, United States Recruiting
Study contacts
- Principal investigator: Carolyn Rodriguez, MD, PhD — Stanford University
- Study coordinator: Alessa Gaeta, BA
- Email: ocdresearch@stanford.edu
- Phone: 650-723-4095
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Low-intensity focused ultrasound targeting the subthalamic nucleus for OCD
A short test is being done to see if a wearable, non-invasive ultrasound device can safely and tolerably help adults with OCD by targeting a brain region called the subthalamic nucleus.
-
Mindfulness-Based Cognitive Therapy for OCD Delivered Online
This study tests a synchronous online MBCT program for adults with OCD to see if it is acceptable and feasible and to explore links between biological markers, OCD severity, and treatment response.
-
Targeted brain stimulation for OCD: test of tTIS on nucleus accumbens
This study tests whether targeted temporal interference stimulation of the nucleus accumbens can help reduce obsessive-compulsive symptoms in adults with OCD, compared with sham stimulation.
-
Anxiety Skills Study: See if video skill training plus therapy helps people with anxiety
This study tests whether a brief video-based skill training can help people with anxiety as well as four therapy sessions, and how durable the effects are over a year.
-
AttunE LIFU for OCD: a non-invasive brain stimulation study
This trial tests ATTN201, a wearable ultrasound headband, to see if it helps adults with OCD compared to a sham treatment.
-
Combined ERP and Habit Reversal Therapy for Tourettic OCD
This study tests whether a merged Exposure and Response Prevention and Habit Reversal Therapy helps adults with Tourettic OCD more than either therapy alone or basic psychoeducation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.